Company · DHR
Healthcare · 1 research article
Danaher's Q3 core sales rose 3% and adjusted EPS 11.5%, but a swing in income tax supplied about 81% of the net earnings increase, and respiratory testing sales fell about 30%.
| Company | View | Revenue YoY | EPS YoY | Guidance | Last report | |
|---|---|---|---|---|---|---|
| DHR Danaher | LONG | +8.5% | — | revised | Oct 21, 2026 | |
| BMY Bristol-Myers Squibb | LONG | +7% | — | raised | Oct 29, 2026 | Compare |
| CVS CVS Health | LONG | +7.3% | — | raised | Aug 5, 2026 | Compare |
| HUM Humana | LONG | — | — | — | — | Compare |
| ISRG Intuitive Surgical | LONG | +22% | — | issued | Oct 20, 2026 | Compare |
| LLY Eli Lilly | LONG | +39% | +7% | raised | Oct 29, 2026 | Compare |
| MRK Merck | LONG | — | — | issued | Oct 29, 2026 | Compare |
| PFE Pfizer | LONG | — | — | — | — | Compare |
Growth figures are year-over-year changes extracted automatically from each company's latest earnings release and can contain errors.
Widgets by TradingView. They load only when you click, so the page stays fast.
Forensic equity research on US stocks. No spam, unsubscribe anytime.
